Between October 2 and October 6, 2026, the French National Agency for the Safety of Medicines and Health Products (ANSM) reported changes in the availability of several medications sold both in pharmacies and hospitals. These updates included some shortages and the restoration of supply for others. The agency is monitoring these issues closely to ensure patients continue receiving necessary treatments. BICAFRES 1000 mg gastro-resistant tablets faced a shortage in both pharmacies and hospitals. The expected return of this medication was delayed from April 2027 to June 2027. In the meantime, pharmacists may provide compounded alternatives without requiring a new prescription to help patients continue their treatment. LEPTICUR 10 mg tablets experienced supply issues in pharmacies, with limited quantities available, though hospitals were unaffected after a period of tension. The ANSM listed several alternative medications that can be prescribed in place of LEPTICUR, including AKINETON LP 4 mg, ARTANE 2 mg and 5 mg, and PARKINANE LP 2 mg and 5 mg. TIORFAN 10 mg NOURRISSONS and TIORFAN 30 mg ENFANTS oral powders in sachets were reported as out of stock by the manufacturer, Bioprojet Pharma. A possible alternative is TIORFAN 4 mg/mL NOURRISSONS ET ENFANTS drinkable suspension, available in 50 mL and 180 mL bottles with syringes. However, the return date for these products remains uncertain. XEPLION 150 mg injectable prolonged release suspension faced supply chain issues, with limited availability for the 150 mg dose in pharmacies. The 150 mg dosage was expected to return by mid-October 2026, while other dosages (100 mg, 75 mg, 50 mg, and 25 mg) were restored to normal supply. All medications based on paliperidone LP, the active ingredient in XEPLION, are currently under supply chain pressure. The ANSM confirmed that CONCERTA LP 18 mg, LP 36 mg, and LP 54 mg prolonged release tablets (methylphenidate hydrochloride) have returned to normal supply since October 2, 2026, after several months of shortages. Additionally, INDOCOLLYRE 0.1% eye drops in solution were restored to availability as of October 1, 2026, as previously announced.